Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/21601
Title: | The cost-effectiveness of pneumococcal vaccination in healthy adults over 50: An exploration of influential factors for Belgium | Authors: | BLOMMAERT, Adriaan Bilcke, Joke WILLEM, Lander Verhaegen, Jan Goossens, Herman Beutels, Philippe |
Issue Date: | 2016 | Publisher: | ELSEVIER SCI LTD | Source: | VACCINE, 34 (18), p. 2106-2112 | Abstract: | Background: A recent trial demonstrated the 13 valent conjugate pneumococcal vaccine (PCV13) to be effective against invasive and non-invasive pneumococcal disease in healthy adults. PCV13 might therefore be considered as an alternative to the 23 valent polysaccharide vaccine (PPV23). Aim: To explore the cost-effectiveness of vaccinating healthy adults over 50, with either PCV13 or PPV23 alone, or with a combined strategy using both PCV13 and PPV23. Methods: A static multi-cohort model was developed simulating the consequences of pneumococcal vaccination in adults over 50 from a health care payer's perspective, for different scenarios of duration of vaccine protection and serotype evolution. Results: At currently expected prices, PCV13 vaccination of healthy adults over 50 is unlikely to be cost-effective either compared with no vaccination or in combination with PPV23 versus PPV23 only. Conclusion: Further research is needed on vaccine efficacy of the combination strategy and of risk groups, as well as the duration of vaccine protection. Serotype evolutions under the influence of the childhood PCV program should be closely monitored. (C) 2016 Elsevier Ltd. All rights reserved. | Notes: | [Blommaert, Adriaan; Bilcke, Joke; Willem, Lander; Beutels, Philippe] Univ Antwerp, Vaccine & Infect Dis Inst VAXINFECTIO, CHERMID, B-2020 Antwerp, Belgium. [Blommaert, Adriaan; Willem, Lander] Univ Hasselt, Interuniv Inst Biostat & Stat Bioinformat I BIOST, Diepenbeek, Belgium. [Willem, Lander] Univ Antwerp, Dept Math & Comp Sci, Middelheimlaan 1, B-2020 Antwerp, Belgium. [Verhaegen, Jan] Univ Ziekenhuis Leuven, Dept Clin Microbiol, Herestr 49, B-3000 Louvain, Belgium. [Goossens, Herman] Univ Antwerp, Vaccine & Infect Dis Inst VAXINFECTIO, Lab Med Microbiol, B-2020 Antwerp, Belgium. [Beutels, Philippe] Univ New S Wales, Sch Publ Hlth & Community Med, Sydney, NSW 2052, Australia. | Keywords: | Pneumococcal vaccine; Economic evaluation; Cost-effectiveness analysis; Pneumonia;pneumococcal vaccine; economic evaluation; cost-effectiveness analysis; pneumonia | Document URI: | http://hdl.handle.net/1942/21601 | ISSN: | 0264-410X | e-ISSN: | 1873-2518 | DOI: | 10.1016/j.vaccine.2016.03.003 | ISI #: | 000374362500010 | Rights: | © 2016 Elsevier Ltd. All rights reserved. | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2017 |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
blommaert 1.pdf Restricted Access | Published version | 545.59 kB | Adobe PDF | View/Open Request a copy |
SCOPUSTM
Citations
22
checked on Sep 2, 2020
WEB OF SCIENCETM
Citations
24
checked on Sep 27, 2024
Page view(s)
64
checked on Sep 6, 2022
Download(s)
42
checked on Sep 6, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.